Investor Presentation Q1-Q3 2020
74
Investor presentation
First nine months of 2020
The stem cell platform has the potential to solve unmet needs
for people with serious chronic diseases
Blastocyst
السمر
stem cells to
Treatment
centres
Patient
transplanted at
treatment centres
Pluripotent
embryonic
stem cells
STEM CELL TECHNOLOGY
Cell bank of
undifferentiated
stem cells
Cell bank
Differentiate
specific cell
types
Partners
Partners
COMPLEMENTARY COMPETENCIES
GMP-grade production capability in US
facility utilising Novo Nordisk's core CMC
capabilities
Ethical stem cell practices
+
↑
+
G
↑
↑ ↑
IP positions on differentiation protocols
گی
Novo Nordisk®
Parkinson's disease
Collaboration with Lund University
and partnership with Biolamina
Type 1 diabetes
Encapsulation device in
collaboration with universities
GO
Chronic kidney disease
Partnership with Mayo Clinic
Dry age-related
macular degeneration
Partnership with Biolamina
Academic collaborations with stem
cell technology experts
Chronic heart failure
Partnership with BiolaminaView entire presentation